Lack	O
of	O
evidence	O
of	O
lower	O
30	O
-	O
day	O
all	O
-	O
cause	O
readmission	B:C0030700
in	O
Medicare	O
beneficiaries	O
with	O
heart	B:C0018801
failure	I:C0018801
and	O
reduced	O
ejection	B:C0232174
fraction	I:C0232174
discharged	B:C0030685
on	O
spironolactone	B:C0037982
.	O

Therapy	B:C0087111
with	O
evidence	O
-	O
based	O
heart	B:C0018801
failure	I:C0018801
(	O
heart	B:C0018801
failure	I:C0018801
)	O
medications	B:C4284232
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
lower	O
risk	O
of	O
30	O
-	O
day	O
all	O
-	O
cause	O
readmission	B:C0030700
in	O
patients	O
with	O
heart	B:C0018801
failure	I:C0018801
and	O
reduced	B:C4022792
ejection	I:C4022792
fraction	I:C4022792
(	O
HF	B:C0012634
and	I:C0012634
reduced	I:C0012634
ejection	I:C0012634
fraction	I:C0012634
)	O
.	O

We	O
examined	B:C0332128
the	O
association	O
of	O
aldosterone	B:C0002007
antagonist	I:C0002007
use	O
with	O
30	O
-	O
day	O
all	O
-	O
cause	O
readmission	B:C0030700
in	O
this	O
population	B:C1257890
.	O

Of	O
the	O
2443	O
Medicare	O
beneficiaries	O
with	O
heart	B:C0018801
failure	I:C0018801
and	O
left	B:C0428772
ventricular	I:C0428772
EF	I:C0428772
≤	O
35	O
%	O
discharged	B:C0184713
home	I:C0184713
from	O
106	O
Alabama	B:C0001895
hospitals	B:C0019994
during	O
1998	O
-	O
2001	O
,	O
2060	O
were	O
eligible	O
for	O
spironolactone	B:C0037982
therapy	B:C0087111
(	O
serum	B:C0600061
creatinine	I:C0600061
≤	O
2.5	O
for	O
men	O
and	O
≤	O
2mg	O
/	O
dl	O
for	O
women	O
,	O
and	O
serum	B:C0302353
potassium	I:C0302353
<	O
5	O
m	O
Eq	O
/	O
L	O
)	O
.	O

After	O
excluding	O
186	O
patients	O
already	O
receiving	O
spironolactone	B:C0037982
on	O
admission	B:C0030673
,	O
the	O
inception	O
cohort	O
consisted	O
of	O
1874	O
patients	O
eligible	O
for	O
a	O
new	O
discharge	B:C0030685
prescription	B:C0033080
for	O
spironolactone	B:C0037982
,	O
of	O
which	O
329	O
received	O
one	O
.	O

Using	O
propensity	O
scores	O
for	O
initiation	O
of	O
spironolactone	B:C0037982
therapy	B:C0087111
,	O
we	O
assembled	O
a	O
matched	O
cohort	B:C0599755
of	O
324	O
pairs	O
of	O
patients	O
receiving	O
and	O
not	O
receiving	O
spironolactone	B:C0037982
balanced	O
on	O
34	O
baseline	O
characteristics	O
(	O
mean	O
age	O
72	O
years	O
,	O
42	O
%	O
women	O
,	O
33	O
%	O
African	B:C0085756
American	I:C0085756
)	O
.	O

Thirty	O
-	O
day	O
all	O
-	O
cause	O
readmission	B:C0030700
occurred	O
in	O
17	O
%	O
and	O
19	O
%	O
of	O
matched	O
patients	O
receiving	O
and	O
not	O
receiving	O
spironolactone	B:C0037982
,	O
respectively	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.92	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.64-1.32	O
;	O
p=0.650	O
)	O
.	O

Spironolactone	B:C0037982
had	O
no	O
association	O
with	O
30	O
-	O
day	O
all	O
-	O
cause	O
mortality	O
(	O
HR	O
,	O
0.84	O
;	O
95	O
%	O
CI	O
,	O
0.38	O
-	O
1.88	O
;	O
p=0.678	O
)	O
or	O
heart	B:C0018801
failure	I:C0018801
readmission	B:C0030700
(	O
HR	O
,	O
0.74	O
;	O
95	O
%	O
CI	O
,	O
0.41	O
1.31	O
;	O
p=0.301	O
)	O
.	O

These	O
associations	O
remained	O
unchanged	O
during	O
12	O
months	O
of	O
post	B:C1320368
-	I:C1320368
discharge	I:C1320368
follow	I:C1320368
-	I:C1320368
up	I:C1320368
.	O

A	O
discharge	B:C0030685
prescription	B:C0033080
for	O
spironolactone	B:C0037982
had	O
no	O
association	O
with	O
30	O
-	O
day	O
all	O
-	O
cause	O
readmission	B:C0030700
among	O
older	O
,	O
hospitalized	O
Medicare	O
beneficiaries	O
with	O
HF	B:C0012634
and	I:C0012634
reduced	I:C0012634
ejection	I:C0012634
fraction	I:C0012634
eligible	O
for	O
spironolactone	B:C0037982
therapy	B:C0087111
.	O

